Feb. 17 at 7:12 PM
$TGTX Repeating what I've said in the past, “TG is not limited — only one drug.” One exceptional horse beats a stable of average ones every time — and Briumvi is that horse in RMS.
It’s not just the best anti-CD20 — the long-term data now makes a strong case it’s the best overall RMS therapy available today:
• ARR 0.020 in Year 5 — one relapse every 50 years on average
• 97.7% relapse-free at Year 5 (continuous treatment)
• 95.0% relapse-free at Year 5 (switch patients)
• 89.9% progression-free at 6 years (confirmed disability progression)
• Slowest brain atrophy in the class
• 94% retention at 5 years — patients stay because it keeps working
Compare to the rest of the field:
Ocrevus: ~80–85% progression-free, higher ARR (~0.1–0.2)
Kesimpta: ~75–85% progression-free, monthly injections, higher relapses
BTK inhibitors (fenebrutinib, etc.): Liver monitoring required, immature long-term data, suicide imbalance signal. continues......
